炎症
鼻粘膜
H&E染色
医学
免疫学
细胞
过敏性炎症
基因沉默
癌症研究
污渍
染色
粘膜炎症
下调和上调
鼻腔给药
药理学
T细胞
病理
信号转导
受体
细胞生长
化学
炎性细胞
剂量依赖性
发病机制
分子生物学
作者
Meng Sun,Xiaojing Zhang,孟薇,Lifeng Zhang,Xiangjing Chen,Xin Zhang,Yunhong Ning,Renzhong Wang
出处
期刊:Immunobiology
[Elsevier BV]
日期:2026-06-27
卷期号:231 (4): 153210-153210
标识
DOI:10.1016/j.imbio.2026.153210
摘要
BACKGROUND: Minimal persistent inflammation (MPI) significantly contributes to the recurrence of allergic rhinitis (AR). Although the therapeutic efficacy of Biminkang mixture (BMK) in AR treatment is well-documented, the precise mechanisms underlying its modulation of MPI remain unclear. METHODS: An MPI mouse model and an interleukin-33 (IL-33)-induced T-helper 2 (Th2) cell model were established. The effects of BMK on nasal mucosa remodeling and inflammation in MPI mice were evaluated using hematoxylin & eosin staining and ELISA. Th2 cell viability was measured using a CCK-8 assay. Western blotting and qRT-PCR were performed to evaluate the effects of BMK on the ST2/ERK/JNK/P38/NF-κB signaling cascade. RESULTS: Administration of BMK notably mitigated nasal mucosa remodeling and inflammation in MPI mice and markedly inhibited IL-33-induced Th2 cell viability. Moreover, BMK inhibited the activation of the ST2/ERK/JNK/P38/NF-κB signaling cascade, and the inhibit effect of BMK on the ERK/JNK/P38/NF-κB pathway was further enhanced by silencing ST2. CONCLUSIONS: These findings suggest that BMK effectively alleviates MPI by targeting the ST2-mediated ERK/JNK/P38/NF-κB pathway, thereby inhibiting nasal mucosa remodeling, inflammation, and Th2 cell viability.
科研通智能强力驱动
Strongly Powered by AbleSci AI